CD262, Mouse Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD262, Mouse antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD262, Mouse |
| Clone | REA1233 |
| Host Species | Recombinant Human |
| Reactive Species | mouse |
| Isotype | IgG1 |
| Format | Vio Bright B515 conjugate |
| Size | 30 µg in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD262 Antibody, anti-mouse, Vio® Bright B515, REAfinity™. Clone REA1233 recognizes the murine CD262 antigen, a protein of the TNF-receptor superfamily, expressed on leukocytes, placenta cells, liver cells and some tumor cells and tumor cell lines (such as NIH-3T3). CD262 is also known as Death receptor 5 (DR5), TRAIL-R2, and TNFRSF10B. CD262 is a receptor for TRAIL, its binding induces apoptosis by activating the NF-κB pathway. | Additional information: Clone REA1233 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | TNFRSF10B, DR5, KILLER, Ly98, MK, TRAIL-R2, TRICK2A, TRICK2B, TRICKB |
| Gene, Accession # | Gene ID: 21933 |
| Catalog # | 130-124-487 |
| Price | $200 |
| Order / More Info | CD262, Mouse Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Hayakawa, Y. et al. (2004) NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 172 (1): 123-129. | Sato, K. et al. (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol (174): 4025-4033. | Takeda, K. et al. (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 4 (199): 437-448. | Grisendi, G. et al. (2010) Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 70 (9): 3718-3729. | Shanker, A. et al. (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J. Natl. Cancer Inst. 100 (9): 649-662. | Iannello, A. et al. (2009) Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J. Virol. 83 (12): 5999-6010. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies